Awakn Life Sciences (TSE:AWKN) has released an update.
Awakn Life Sciences Corp., a biotech firm focused on substance use and mental health disorders, is advancing its patent portfolio for its aminoindane compounds, which show promise in treating conditions like PTSD. The company’s international patent applications are making significant progress, with positive feedback from the U.S. and European patent offices indicating a strong likelihood of patent grants.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.
